Pfizer Recalls Lot of Neurontin
Pfizer Recalls Lot of Neurontin
Pfizer (New York, NY, www.pfizer.com) has voluntarily recalled one lot (40,000 bottles) of its epilepsy medication "Neurontin." According to the company, a manufacturing mechanical failure resulted in some bottles containing empty or partially filled capsules.
The recall affects only 100-mg capsules from lot #15224V, distributed during October and November 2004, only in the United States. The company said it is possible that patients taking Neurontin could experience seizures from a missed dose of the product, and patients should consult with their physician before discontinuing the drug.
Pfizer said the recall of the affected lot will not result in a shortage of Neurontin 100-mg capsules. Consumers are encouraged to contact Pfizer Medical Information at 800.438.1985 if they have any questions about the recall.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
